Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.
Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D, Pereira DS, Jimenez X, Fox F, Saxena B, Zhou Q, Ma Y, Kang X, Patel D, Barry M, Kussie P, Zhu Z, Russell DA, Petersen WL, Jury TP, Gaitan-Gaitan F, Moran DL, Delannay X, Storrs BS, Tou J, Zupec ME, Gustafson KS, McIntyre J, Tarnowski SJ, Bohlen P. Ludwig DL, et al. Among authors: fox f. Hum Antibodies. 2004;13(3):81-90. Hum Antibodies. 2004. PMID: 15598988
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Spratlin JL, et al. Among authors: fox f. J Clin Oncol. 2010 Feb 10;28(5):780-7. doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048182 Free PMC article. Clinical Trial.
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ. Chiorean EG, et al. Among authors: fox fe. Ann Oncol. 2015 Jun;26(6):1230-1237. doi: 10.1093/annonc/mdv144. Epub 2015 Mar 18. Ann Oncol. 2015. PMID: 25787923 Free article. Clinical Trial.
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE. Kuenen B, et al. Among authors: fox f. Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2. Clin Cancer Res. 2010. PMID: 20197484 Free article. Clinical Trial.
229 results